Needham & Company LLC Reaffirms Hold Rating for Neurocrine Biosciences (NASDAQ:NBIX)

Needham & Company LLC restated their hold rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research report sent to investors on Monday morning,Benzinga reports.

Several other brokerages also recently commented on NBIX. Piper Sandler raised Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $131.00 to $159.00 in a research note on Thursday, August 29th. Robert W. Baird increased their price objective on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Jefferies Financial Group boosted their target price on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Royal Bank of Canada dropped their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. Finally, Citigroup boosted their price objective on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $127.17 on Monday. Neurocrine Biosciences has a 52 week low of $106.85 and a 52 week high of $157.98. The stock has a market capitalization of $12.88 billion, a P/E ratio of 34.09 and a beta of 0.35. The stock has a fifty day moving average of $118.43 and a 200-day moving average of $132.99.

Insider Transactions at Neurocrine Biosciences

In related news, Director William H. Rastetter sold 14,250 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the transaction, the director now owns 37,491 shares in the company, valued at $5,499,554.79. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. RFP Financial Group LLC raised its position in shares of Neurocrine Biosciences by 346.5% during the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after purchasing an additional 149 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences during the second quarter worth $28,000. Innealta Capital LLC bought a new position in shares of Neurocrine Biosciences in the second quarter valued at $30,000. New Covenant Trust Company N.A. acquired a new position in shares of Neurocrine Biosciences during the first quarter valued at about $32,000. Finally, EdgeRock Capital LLC bought a new stake in shares of Neurocrine Biosciences during the second quarter worth about $35,000. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.